Yourgene Health plc
("Yourgene" or the "Company")
Capital Markets Day
Manchester, UK - 6 April 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it will be holding a Capital Markets Day for investors on Tuesday 26 April 2022.
The event will provide investors with a compelling opportunity to hear more from other senior members of the management team about the roadmap and growth plans for certain products and services, both in North America and internationally, as well as perspectives on the dynamics within the molecular diagnostics market and the scope for growing the Company's genomic services business.
An opening and closing address will be given by CEO, Lyn Rees who will provide an overview of the Company and where it is currently positioned. The event will also feature presentations by:
· Dr Rachel Shelmerdine, Product Management
· Scott Sargent, Vice President, Sales Americas
· Bhavika Patel, Technical Director, Yourgene Genomic Services
· Jonathan Seaton, Non-Executive Director, Yourgene Health plc
The event will be repeated in the City of London at 4pm for non-institutional investors and will be followed by light refreshments and an opportunity to talk to the senior management further.
To register your interest please contact Walbrook PR on 020 7933 8780 or email yourgene@walbrookpr.com.
|
Yourgene Health plc Lyn Rees, Chief Executive Officer |
Tel: +44 (0)161 669 8122 |
|
|
Barry Hextall, Chief Financial Officer |
|
|
|
Joanne Cross, Director of Marketing |
|
|
|
|
|
|
|
Singer Capital Markets (Joint Corporate Broker) |
Tel: +44 (0)20 7496 3000 |
|
|
Aubrey Powell / Tom Salvesen / George Tzimas |
|
|
|
|
|
|
|
Stifel Nicolaus Europe Limited (Joint Corporate Broker) |
Tel: +44 (0)20 7710 7600 |
|
|
Nicholas Moore / Matthew Blawat / Ben Maddison |
|
|
|
|
|
|
|
Walbrook PR Ltd (Media and Investor Relations) |
Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com |
|
|
Paul McManus / Lianne Applegarth / Alice Woodings |
Mob: 07980 541 893 / Mob: 07584 391 303 Mob: 07407 804 654 |
|
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach†in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
